JP2001523712A5 - - Google Patents

Download PDF

Info

Publication number
JP2001523712A5
JP2001523712A5 JP2000521818A JP2000521818A JP2001523712A5 JP 2001523712 A5 JP2001523712 A5 JP 2001523712A5 JP 2000521818 A JP2000521818 A JP 2000521818A JP 2000521818 A JP2000521818 A JP 2000521818A JP 2001523712 A5 JP2001523712 A5 JP 2001523712A5
Authority
JP
Japan
Prior art keywords
cycloalkyl
pharmaceutically acceptable
general formula
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2000521818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001523712A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/023482 external-priority patent/WO1999026616A1/en
Publication of JP2001523712A publication Critical patent/JP2001523712A/ja
Publication of JP2001523712A5 publication Critical patent/JP2001523712A5/ja
Abandoned legal-status Critical Current

Links

JP2000521818A 1997-11-25 1998-11-04 Ｐｄｅ−ｉｖのベンゼンスルホンアミド阻害剤およびそれらの治療的使用 Abandoned JP2001523712A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6694397P 1997-11-25 1997-11-25
US60/066,943 1997-11-25
PCT/US1998/023482 WO1999026616A1 (en) 1997-11-25 1998-11-04 Benzenesulfonamide inhibitors of pde-iv and their therapeutic use

Publications (2)

Publication Number Publication Date
JP2001523712A JP2001523712A (ja) 2001-11-27
JP2001523712A5 true JP2001523712A5 (enExample) 2006-01-05

Family

ID=22072726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000521818A Abandoned JP2001523712A (ja) 1997-11-25 1998-11-04 Ｐｄｅ−ｉｖのベンゼンスルホンアミド阻害剤およびそれらの治療的使用

Country Status (15)

Country Link
US (1) US6162830A (enExample)
EP (1) EP1045690B1 (enExample)
JP (1) JP2001523712A (enExample)
KR (1) KR20010024268A (enExample)
AT (1) ATE238048T1 (enExample)
AU (1) AU751453C (enExample)
BR (1) BR9812527A (enExample)
CA (1) CA2299399C (enExample)
DE (1) DE69813895T2 (enExample)
DK (1) DK1045690T3 (enExample)
ES (1) ES2195419T3 (enExample)
NZ (1) NZ502965A (enExample)
PT (1) PT1045690E (enExample)
WO (1) WO1999026616A1 (enExample)
ZA (1) ZA9810735B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
JP3940290B2 (ja) * 2000-12-22 2007-07-04 ザ・ヨルダニアン・フアーマシユーテイカル・エム・エフ・ジー・アンド・メデイカル・イクイツプメント・カンパニー・リミテツド 新規化合物
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
SE0004780D0 (sv) 2000-12-22 2000-12-22 Jordanian Pharmaceutical Mfg & Novel compunds
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) * 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
DE60324104D1 (en) * 2002-01-30 2008-11-27 Amgen Inc Arylsulfonamidobenzylverbindungen
AU2003208952B2 (en) * 2002-01-30 2008-04-24 Amgen Inc. Heterocyclic arylsulfonamidobenzylic compounds
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CN1658848A (zh) * 2002-04-12 2005-08-24 细胞基因公司 血管生成调节剂的鉴定方法,由此发现的化合物和使用该化合物的治疗方法
ES2195785B1 (es) * 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
MXPA05000827A (es) 2002-07-19 2005-08-29 Memory Pharm Corp Inhibidores de fosfodiesterasa 4, incluyendo analogos de anilina y difenilamina n-sustituidos.
CN101423497A (zh) * 2002-07-19 2009-05-06 记忆药物公司 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑和4-氨基苯并呋喃化合物
RU2356893C2 (ru) * 2002-11-19 2009-05-27 Мемори Фармасьютиклз Корпорейшн Ингибиторы фосфодиэстеразы 4
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US20060264424A1 (en) * 2003-08-12 2006-11-23 Tularik Inc Arylsulfonamidobenzylic compounds
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
WO2009120296A1 (en) * 2008-03-24 2009-10-01 Celgene Corporation Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
FR2962649B1 (fr) 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
CN111925313B (zh) * 2020-09-22 2021-06-25 纳兰迦(上海)生物医药科技有限公司 具有pde4抑制活性的化合物、制备方法、组合物及用途
JP7769365B2 (ja) * 2021-09-22 2025-11-13 日本メナード化粧品株式会社 皮膚幹細胞増殖促進剤及び皮膚再生促進剤
EP4197318B1 (en) * 2021-12-17 2025-11-19 Albert-Ludwigs-Universität Freiburg Phosphodiesterases inhibitors to promote in vitro plant cell reprogramming towards plant embryogenesis or microcallus formation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
IL106517A0 (en) * 1992-07-28 1994-08-26 Rhone Poulenc Rorer Ltd Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5728712A (en) * 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772296A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772396A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
JP2000510866A (ja) * 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンスルホンアミド

Similar Documents

Publication Publication Date Title
WO2006060029A3 (en) Insecticidal n-substituted sulfoximines
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
JP2004530641A5 (enExample)
NZ541974A (en) Nucleotide phosphoramidates as anticancer agents
CA2470183C (en) Intermediates for preparing arylsulphonamides and analogues
EP1087960A4 (en) MACROCYCLIC ANALOGUES AND METHOD FOR THEIR USE AND MANUFACTURE
JP2002543183A5 (enExample)
JP2003531118A5 (enExample)
AP2000001786A0 (en) Therapeutic uses of quinoline derivatives.
IL154350A (en) Phenylalanine derivatives and pharmaceutical preparations containing them
WO2001087845A3 (en) N-containing heterocyclic compounds and their use as 5-ht antagonists
AU1099302A (en) Medicinal compositions for concominant use as anticancer atent
KR970704697A (ko) 2-[(디히드로)피라졸릴-3'-옥시메틸렌] 아닐리드의 살충제 및 살진균제로서의 용도 (Use of 2-[(Dihydro)Pyrazolyl-3'-Oxymethylene]-Anilides as Pest-Control Agents and Fungicides)
EP1191614A3 (en) Luminescence device and metal coordination compound therefor
TR200300544T1 (tr) Erimiş siklik bileşimler ve tıbbi kullanımları
EP0738716A3 (en) Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
JPH1180090A5 (enExample)
JP2001525394A5 (enExample)
JP2002155281A5 (enExample)
EP1500652A4 (en) DERIVATIVE AND MEDICINAL PRODUCT OF QUINAZOLINE
CA2013599A1 (en) Aryl-substituted rhodanine derivatives
EP1241158A4 (en) CONNECTION WITH HYDROXYCARBONYL HALOGENALKYL SIDE CHAIN
KR960703405A (ko) 항-히스타민 및 항-알레르기 활성을 갖는 테트라졸 유도체(tetrazole derivatives having antihistaminic and antiallergic activity)
EP0671390A3 (en) Antithrombotic agents
PT1226122E (pt) Agonistas biciclicos da vasopressina